International Flavors & Fragrances (IFF) Q3 2024 earnings summary

Executive summary

• Achieved solid Q3 2024 results with 4% net sales growth to $2.93B, broad-based volume gains, and double-digit EBITDA growth, driven by productivity and innovation investments.

• Raised full-year 2024 guidance for net sales and adjusted operating EBITDA, reflecting strong performance and improved margins.

• Progressed on portfolio optimization, including completed divestitures and the planned sale of Pharma Solutions in H1 2025.

• Opened new creative centers in Shanghai, Mexico City, and India to support innovation and regional growth.

• Employee engagement and organizational focus improved, supporting execution and innovation.

Financial highlights

• Q3 2024 revenue was $2.93B (+4% year-over-year), with comparable currency-neutral sales up 9% and gross profit up 14% to $1.05B.

• Comparable adjusted operating EBITDA rose 16% to $568M (19.4% margin), with adjusted EPS ex amortization at $1.04 (+17%).

• Free cash flow year-to-date reached $399M; cash from operations totaled $702M.

• Net income attributable to shareholders was $59M, up 136% from Q3 2023.

• Net debt to credit adjusted EBITDA improved to 3.9x; total debt at $9.1B, cash and equivalents at $569M.

Outlook and guidance

• Full-year 2024 net sales expected at $11.3B–$11.4B, with adjusted operating EBITDA at the high end of $2.1B–$2.17B.

• Volume growth forecast raised to 5–6%, with pricing impact expected to be flat due to FX headwinds.

• FX expected to have a 3% adverse impact on full-year sales growth.

• Management remains cautiously optimistic for Q4 amid macroeconomic and geopolitical uncertainties.

• Committed to reducing net debt-to-credit-adjusted EBITDA below 3x post-Pharma Solutions sale.